ArticleInternational journal of clinical and experimental pathology2026
Increased expression of SMAD5-AS1 in glioma is associated with patient prognosis and immunity.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to examine the expression profile, clinical significance, and potential diagnostic/prognostic value of the long non-coding RNA (lncRNA) SMAD5-AS1 in glioma.
methodsExpression of SMAD5-AS1 and its associations with survival were analyzed in patients with lower-grade glioma (LGG) and glioblastoma (GBM) using GEPIA2, R, UALCAN, and TIMER3 platforms.
resultsSMAD5-AS1 was significantly upregulated in multiple cancers, particularly gliomas (LGG and GBM; P < 0.05), demonstrating strong diagnostic performance for GBM (AUC = 0.87) and moderate performance for LGG (AUC = 0.71). In LGG, high SMAD5-AS1 expression was associated with poorer overall survival (HR = 25.53; P < 0.001) and enrichment in higher-grade tumors and astrocytic subtypes (P < 0.01), suggesting a link to tumor aggressiveness. Furthermore, SMAD5-AS1 expression was negatively correlated with infiltration by immunosuppressive cells, implicating a role in modulating the tumor immune microenvironment.
conclusionSMAD5-AS1 represents a promising diagnostic and prognostic biomarker in glioma, with elevated expression linked to increased tumor aggressiveness, immunosuppression, and adverse patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.